Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer
Source: The Motley Fool
Boudry :: Switzerland | updated 2013-05-23 04:59:27 -0700 | health-news
The FDA grants Priority Review to medicines that, if approved, have the potential to offer significant improvement compared to marketed products or provide a treatment where no adequate therapy exists. The goal for completing a Priority Review is six months.
Cartoons of The Day
Contributors
Build Your Allvoices Brand. Gain Influence. Make Money.
News From Hot Locations
